A dysregulated interleukin-18-interferon-γ-CXCL9 axis impacts treatment response to canakinumab in systemic juvenile idiopathic arthritis.

Tanja HinzeChristoph KesselClaas H HinzeJulia SeibertHermann GramDirk Foell

Published in: Rheumatology (Oxford, England) (2021)

Differential regulation of the IL-18-IFN-γ-CXCL9 axis is observed in patients with SJIA. Higher IL-18: CXCL9 and IFN-γ: CXCL9 ratios at baseline are associated with a better clinical response to canakinumab treatment in SJIA. Future studies are needed to validate these findings and determine their generalizability to patients with recent MAS.

Keyphrases

juvenile idiopathic arthritis
dendritic cells

immune response
disease activity

rheumatoid arthritis

systemic lupus erythematosus